Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

Clinical trial NCT07660094 · RECRUITING

Trial details

NCT number: NCT07660094
Sponsor: Candel Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-squamous, Non-Small Cell Lung Cancer

Start date: 2026-06-15
Primary completion: 2031-10-22
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.